Compare UROY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UROY | TECX |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 60 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.8M | 554.1M |
| IPO Year | N/A | N/A |
| Metric | UROY | TECX |
|---|---|---|
| Price | $3.61 | $27.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $75.20 |
| AVG Volume (30 Days) | ★ 2.2M | 225.9K |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $14.39 |
| 52 Week High | $5.52 | $35.99 |
| Indicator | UROY | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 46.21 |
| Support Level | $3.54 | $27.39 |
| Resistance Level | $4.07 | $31.42 |
| Average True Range (ATR) | 0.24 | 1.80 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 5.52 | 34.59 |
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.